Breast Conservation after Neoadjuvant Chemotherapy for Stage II Carcinoma of the Breast

Abstract
Conclusions Neoadjuvant chemotherapy can be effectively applied to patients with stage II disease, and breast conservation becomes feasible in the majority of patients. When compared with historic controls, the current study suggests a statistically significant overall survival advantage (p < 0.007) at 5 years.